

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number  
**WO 2005/017136 A1**

(51) International Patent Classification<sup>7</sup>: C12N 9/06,  
15/62, C12Q 1/37, 1/26, G01N 33/72

(21) International Application Number:  
PCT/US2004/022908

(22) International Filing Date: 16 July 2004 (16.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/622,893 17 July 2003 (17.07.2003) US

(71) Applicant (for all designated States except US): GEN-  
ERAL ATOMICS [US/US]; 3550 General Atomics Court,  
P.O. Box 85608, San Diego, CA 92186-5608 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YUAN,  
Chong-Sheng [US/US]; 3590 Torrey View Court,  
San Diego, CA 92130 (US). DATTA, Abhijit [US/US];  
6426 La Garza Court, Carlsbad, CA 92009 (US). WANG,  
Yuping [CN/US]; 8856 Gainsborough Avenue, San Diego,  
CA 92009 (US).

(74) Agents: CHEN, Peng et al.; Morrison & Foerster LLP,  
3811 Valley Centre Drive, Suite 500, San Diego, CA  
92130-2332 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).


**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOSITIONS FOR DETERMINATION OF GLYCATED PROTEINS

Method Comparison  $y = 1.0578x - 28.772$   
 $R^2 = 0.974$



(57) Abstract: This invention relates generally to  
the field of glycated protein detection. In particular,  
the invention provides chimeric proteins, nucleic  
acids encoding the chimeric proteins, methods and  
kits for assaying for a glycated protein in a sample,  
using inter alia, an amadoriase.

WO 2005/017136 A1

## METHODS AND COMPOSITIONS FOR DETERMINATION OF GLYCATED PROTEINS

## BACKGROUND OF THE INVENTION

[0001] A glycated protein is a substance which is produced by the non-enzymatic and irreversible binding of the amino group of an amino acid constituting a protein, with the aldehyde group of a reducing sugar such as aldose. *See e.g.*, U.S. Patent No. 6,127,138. Such a non-enzymatic and irreversible binding reaction is also called "Amadori rearrangement," and therefore the above-mentioned glycated protein may also be called "Amadori compound" in some cases.

[0002] Nonenzymatic glycation of proteins has been implicated in the development of certain diseases, *e.g.*, diabetic complications and the aging process (Takahashi et al., *J. Biol. Chem.*, 272(19):12505-7 (1997); and Baynes and Monnier, *Prog. Clin. Biol. Res.*, 304:1-410 (1989)). This reaction leads to dysfunction of target molecules through formation of sugar adducts and cross-links. Considerable interest has focused on the Amadori product that is the most important "early" modification during nonenzymatic glycation *in vitro* and *in vivo*.

[0003] Various assays for glycated proteins are known. For example, U.S. Patent No. 6,127,138 discloses that a sample containing a glycated protein is treated with Protease XIV or a protease from *Aspergillus* genus, thereafter (or while treating the sample with the above protease) FAOD (fructosyl amino acid oxidase) is caused to react with the sample so as to measure the amount of oxygen consumed by the FAOD reaction or the amount of the resultant reaction product, thereby to measure the glycated protein.

[0004] In another example, U.S. Patent No. 6,008,006 discloses that the amount of glycated proteins in a sample can be quantified by reacting the sample with first a reagent which is a combination of a protease and a peroxidase and second with a ketoamine oxidase. U.S. Patent No. 6,008,006 also discloses a kit which contains the combined peroxidase/protease enzyme reagent and also the ketoamine oxidase.

## BRIEF SUMMARY OF THE INVENTION

[0005] In one aspect, the present invention is directed to an isolated chimeric protein, which chimeric protein comprises, from N-terminus to C-terminus: a) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and b) a second peptidyl fragment comprising an amadoriase.

[0006] In another aspect, the present invention is directed to an isolated nucleic acid comprising a nucleotide sequence encoding a chimeric protein, which chimeric protein

comprises, from N-terminus to C-terminus: a) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and b) a second peptidyl fragment comprising an amadoriase. Recombinant cells comprising the nucleic acid and methods for producing the chimeric protein using the nucleic acid are also provided.

**[0007]** In still another aspect, the present invention is directed to a method for assaying for a glycosylated protein in a sample, which method comprises: a) contacting a sample to be assayed with a protease to generate a glycosylated peptide or a glycosylated amino acid from a glycosylated protein, if contained in said sample; b) contacting said generated glycosylated peptide or glycosylated amino acid with a chimeric protein comprising, from N-terminus to C-terminus: i) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and ii) a second peptidyl fragment comprising an amadoriase, to oxidize said glycosylated peptide or glycosylated amino acid; and c) assessing oxidation of said glycosylated peptide or glycosylated amino acid by said chimeric protein to determine the presence and/or amount of said glycosylated protein in said sample.

**[0008]** In yet another aspect, the present invention is directed to a kit for assaying for a glycosylated protein in a sample, which kit comprises: a) a protease to generate glycosylated peptide or glycosylated amino acid from a glycosylated protein, if contained in a sample; b) the above-described chimeric protein to oxidize said glycosylated peptide or glycosylated amino acid; and c) means for assessing oxidation of said glycosylated peptide or glycosylated amino acid by said chimeric protein to determine the presence and/or amount of said glycosylated protein in said sample.

**[0009]** In yet another aspect, the present invention is directed to a method for assaying for a glycosylated protein in a sample, which method comprises: a) contacting a sample to be assayed with a proteinase K to generate a glycosylated peptide or a glycosylated amino acid from a glycosylated protein, if contained in said sample; b) contacting said generated glycosylated peptide or glycosylated amino acid with an amadoriase to oxidize said glycosylated peptide or glycosylated amino acid; and c) assessing oxidation of said glycosylated peptide or glycosylated amino acid by said amadoriase to determine the presence and/or amount of said glycosylated protein in said sample.

**[0010]** In yet another aspect, the present invention is directed to a kit for assaying for a glycosylated protein in a sample, which kit comprises: a) a proteinase K to generate a glycosylated peptide or a glycosylated amino acid from a glycosylated protein, if contained in said sample; b) an amadoriase to oxidize said glycosylated peptide or glycosylated amino acid; and c) means for assessing oxidation of said glycosylated peptide or glycosylated amino acid by said amadoriase to determine the presence and/or amount of said glycosylated protein in said sample.

## BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

- [0011] Figure 1 illustrates a comparison between an exemplary GSP kit and a Randox Fructosamine kit.
- [0012] Figure 2 illustrates assay linearity of an exemplary method for assaying for a glycated protein in a sample.
- [0013] Figures 3 and 4 show the dose-dependent reaction with fructosyl-valine.
- [0014] Figure 5 shows the dose-dependent signal with patient hemoglobin digested with a proteinase (5 min. digestion).

## DETAILED DESCRIPTION OF THE INVENTION

- [0015] For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections that follow.


### A. Definitions

- [0016] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this invention belongs. All patents, applications, published applications and other publications referred to herein are incorporated by reference in their entirety. If a definition set forth in this section is contrary to or otherwise inconsistent with a definition set forth in the patents, applications, published applications and other publications that are herein incorporated by reference, the definition set forth in this section prevails over the definition that is incorporated herein by reference.
- [0017] As used herein, "a" or "an" means "at least one" or "one or more."
- [0018] As used herein, a "leader sequence" refers to a peptide sequence, when fused to a target peptide or protein, increases stability and/or expression level of the target peptide or protein. Normally, a leader sequence increases stability and/or expression level of the target peptide or protein for at least 50%. Preferably, a leader sequence increases stability and/or expression level of the target peptide or protein for at least 1 fold, 2 folds, 5 folds, 10 folds or more than 10 folds. In the regulation of gene expression for enzymes concerned with amino acid synthesis in prokaryotes, the leader sequence codes for the leader peptide that contains several residues of the amino acid being regulated. Transcription is closely linked to translation, and if translation is retarded by limited supply of aminoacyl tRNA for the specific amino acid, the mode of transcription of the leader sequence permits full transcription of the

operon genes; otherwise complete transcription of the leader sequence prematurely terminates transcription of the regulated gene.

**[0019]** As used herein, a “glycated protein” refers to a substance which is produced by the non-enzymatic and irreversible binding of the amino group of an amino acid constituting a protein, with the aldehyde group of a reducing sugar such as aldose. *See e.g.*, U.S. Patent No. 6,127,138. Such a non-enzymatic and irreversible binding reaction is also called “Amadori rearrangement,” and therefore the above-mentioned glycated protein may also be called “Amadori compound” in some cases.

**[0020]** As used herein, an “amadoriase” refers to an enzyme catalyzing the oxidative deglycation of Amadori products to yield corresponding amino acids, glucosone, and H<sub>2</sub>O<sub>2</sub>, as shown in the following reaction:



wherein, R<sub>1</sub> represents the aldose residue of a reducing sugar and R<sub>2</sub> represents a residue of an amino acid, protein or peptide. Other synonyms of amadoriase include fructosyl amino acid oxidase (FAOD) and fructosyl amine:oxygen oxidoreductase (FAOO). For purposes herein, the name “amadoriase” is used herein, although all such chemical synonyms are contemplated. “Amadoriase” also encompasses a functional fragment or a derivative that still substantially retain its enzymatic activity catalyzing the oxidative deglycation of Amadori products to yield corresponding amino acids, glucosone, and H<sub>2</sub>O<sub>2</sub>. Typically, a functional fragment or derivative retains at least 50% of its amadoriase activity. Preferably, a functional fragment or derivative retains at least 60%, 70%, 80%, 90%, 95%, 99% or 100% of its amadoriase activity. It is also intended that an amadoriase can include conservative amino acid substitutions that do not substantially alter its activity. Suitable conservative substitutions of amino acids are known to those of skill in this art and may be made generally without altering the biological activity of the resulting molecule. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (*see, e.g.*, Watson, *et al.*, *Molecular Biology of the Gene*, 4th Edition, 1987, The Bejacmin/Cummings Pub. Co., p. 224). Such exemplary substitutions are preferably made in accordance with those set forth in TABLE 1 as follows:

**TABLE 1**

<b>Original residue</b>	<b>Conservative substitution</b>
Ala (A)	Gly; Ser
Arg (R)	Lys
Asn (N)	Gln; His
Cys (C)	Ser
Gln (Q)	Asn
Glu (E)	Asp
Gly (G)	Ala; Pro
His (H)	Asn; Gln
Ile (I)	Leu; Val
Leu (L)	Ile; Val
Lys (K)	Arg; Gln; Glu
Met (M)	Leu; Tyr; Ile
Phe (F)	Met; Leu; Tyr
Ser (S)	Thr
Thr (T)	Ser
Trp (W)	Tyr
Tyr (Y)	Trp; Phe
Val (V)	Ile; Leu

Other substitutions are also permissible and may be determined empirically or in accord with known conservative substitutions.

**[0021]** As used herein, "glycohemoglobin" refers to a fructosylamine derivative produced by the glycation of hemoglobin in blood.

**[0022]** As used herein, "glycoalbumin" refers to a fructosylamine derivative produced by the glycation of albumin in blood.

**[0023]** As used herein, "fructosamine" refers to a derivative (having a reducing ability) produced by the glycation of a protein in blood.

**[0024]** As used herein, a "composition" refers to any mixture of two or more products or compounds. It may be a solution, a suspension, liquid, powder, a paste, aqueous, non-aqueous, or any combination thereof.

**[0025]** As used herein, a "combination" refers to any association between two or among more items.

**[0026]** As used herein, "plasma" refers to the fluid, noncellular portion of the blood, distinguished from the serum obtained after coagulation.

**[0027]** As used herein, "serum" refers to the fluid portion of the blood obtained after removal of the fibrin clot and blood cells, distinguished from the plasma in circulating blood.

[0028] As used herein, "fluid" refers to any composition that can flow. Fluids thus encompass compositions that are in the form of semi-solids, pastes, solutions, aqueous mixtures, gels, lotions, creams, and other such compositions.

[0029] As used herein, "peroxidase" refers to an enzyme that catalyses a host of reactions in which hydrogen peroxide is a specific oxidizing agent and a wide range of substrates act as electron donors. It is intended to encompass a peroxidase with conservative amino acid substitutions that do not substantially alter its activity. The chief commercially available peroxidase is horseradish peroxidase.

[0030] As used herein, "glucose oxidase" refers to an enzyme that catalyzes the formation of gluconic acid and  $H_2O_2$  from glucose,  $H_2O$  and  $O_2$ . It is intended to encompass glucose oxidase with conservative amino acid substitutions that do not substantially alter its activity.

[0031] As used herein, "hexokinase" refers to an enzyme that catalyses the transfer of phosphate from ATP to glucose to form glucose-6-phosphate, the first reaction in the metabolism of glucose via the glycolytic pathway. It is intended to encompass hexokinase with conservative amino acid substitutions that do not substantially alter its activity.

[0032] As used herein, the abbreviations for any protective groups, amino acids and other compounds, are in accord with their common usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature, unless otherwise indicated (*see Biochemistry* 11: 1726 (1972)).

## **B. Chimeric proteins comprising an amadoriase and nucleic acids encoding the same**

[0033] In one aspect, the present invention is directed to an isolated chimeric protein, which chimeric protein comprises, from N-terminus to C-terminus: a) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and b) a second peptidyl fragment comprising an amadoriase.

[0034] Any suitable bacterial leader sequences can be used. As disclosed in U.S. Patent No. 6,194,200, expression of the polypeptide of interest as a fused protein with a leader sequence from another gene has several advantages in addition to providing for stability. For example, the presence of the N-terminal amino acids provides a means for using general purification techniques for purification of any of a variety of polypeptides. For example, the N-terminal amino acids of the N-protein are predictably antigenic, and thus specific antibodies raised against the N-terminal amino acids of the N-protein may be used for the amino

purification of the fusion proteins containing the N-terminus of the N-protein. Furthermore, the N-terminus of the N-protein has a high positive charge, which facilitates purification of the desired protein by ion-exchange chromatography, and the like.

**[0035]** The leader sequence can also be a hydrophobic amino acid sequence, which may additionally function as a signal sequence for secretion. *See* U.S. Patent No. 6,194,200. A DNA sequence encoding the signal sequence is joined upstream from and in reading frame with the gene of interest. Typically, the signal sequence includes a cleavage site which is recognized by a signal sequence peptidase. Thus, positioning the polypeptide of interest directly after the signal sequence cleavage site will allow it to be specifically cleaved from the signal sequence and secreted as a mature polypeptide. Examples of hydrophobic amino acid sequences include the bacterial alkaline phosphatase signal sequence; the OMP-A, B, C, D, E or F signal sequences; the LPP signal sequence,  $\beta$ -lactamase signal sequence; and toxin signal sequences.

**[0036]** Other leader sequences which can be used include hydrophilic sequences, for example the N-terminal 41 amino acid residues from amphiregulin which may provide for modification of the function of the polypeptide of interest. *See* U.S. Patent No. 6,194,200. In addition, a cytotoxic agent such as a toxin A-chain fragment, ricin A-chain, snake venom growth arresting peptide, or a targeting molecule such as a hormone or antibody can be coupled covalently with the leader sequence with in most cases minimal effect on the biological activity of the gene product of interest. As with the other leader sequences, a DNA sequence encoding the leader sequence is joined upstream from and in reading frame with the gene of interest.

**[0037]** Where the leader sequence is not a signal sequence or does not contain a convenient natural cleavage site, additional amino acids may be inserted between the gene of interest and the leader sequence to provide an enzymatic or chemical cleavage site for cleavage of the leader peptide, following purification of the fusion protein, to allow for subsequent purification of the mature polypeptide. *See* U.S. Patent No. 6,194,200. For example, introduction of acid-labile aspartyl-proline linkages between the two segments of the fusion protein facilitates their separation at low pH. This method is not suitable if the desired polypeptide is acid-labile. The fusion protein may be cleaved with, for example, cyanogen bromide, which is specific for the carboxy side of methionine residues. Positioning a methionine between the leader sequence and the desired polypeptide would allow for release of



the desired polypeptide. This method is not suitable when the desired polypeptide contains methionine residues.

**[0038]** Other bacterial leader sequences disclosed in the following patents, patent application and references can also be used: WO 00/28041 and WO 89/03886; U.S. Patent Nos. 5914250, 5885811, 5171670, 5030563, 4948729 and 4588684; EP Patent Nos. EP 0,196,864, EP 0,186,643 and EP 0,121,352; Michiels et al., *Trends Microbiol.*, 9(4):164-8 (2001); Hobom et al., *Dev. Biol. Stand.*, 84:255-62 (1995); Hardy and Randall, *J. Cell. Sci. Suppl.*, 11:29-43 (1989); Saier et al., *FASEB J.*, 2(3):199-208 (1988); and Peakman et al., *Nucleic Acids Res.*, 20(22):6111-2 (1992). Preferably, the bacterial leader sequence is a leader sequence of an *E.coli*. protein, e.g., the *E.coli*. leader sequences disclosed in Roesser and Yanofsky, *Nucleic Acids Res.*, 19(4):795-800 (1991); and Kuhn et al., *Mol. Gen. Genet.*, 167(3):235-41 (1979).

**[0039]** In one example, the leader sequence has at least 40% identity to the amino acid sequence set forth in SEQ ID NO:1 (MGSGDDDDLAL), in which the percentage identity is determined over an amino acid sequence of identical size to the amino acid sequence set forth in SEQ ID NO:1. Preferably, the leader sequence has at least 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO:1, in which the percentage identity is determined over an amino acid sequence of identical size to the amino acid sequence set forth in SEQ ID NO:1. Also preferably, the leader sequence binds to an antibody that specifically binds to an amino acid sequence set forth in SEQ ID NO:1. Still preferably, the leader sequence comprises the amino acid sequence set forth in SEQ ID NO:1.

**[0040]** The first peptidyl fragment can have any suitable length. For example, the first peptidyl fragment comprises about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acid residues. Preferably, the first peptidyl fragment comprises about 20 amino acid residues.

**[0041]** Any suitable amadoriase can be used. In one example, the amadoriase is of *Aspergillus sp.* origin (See e.g., Takahashi et al., *J. Biol. Chem.*, 272(6):3437-43 (1997)). In another example, the amadoriase uses FAD as a cofactor. Preferably, the amadoriase has a FAD cofactor-binding consensus sequence Gly-X-Gly-X-X-Gly (SEQ ID NO:2), X being any amino acid residue. In still another example, the amadoriase is amadoriase Ia, amadoriase Ib, amadoriase Ic or amadoriase II (See e.g., Takahashi et al., *J. Biol. Chem.*, 272(6):3437-43 (1997)). Amino acid sequence homology between the N-terminal sequence of amadoriases Ia, amadoriase Ib, amadoriase Ic and amadoriase II is shown in the following Table 2. These data

were obtained by a computerized search using the combined GenBank™ CDS translations/PDB/SwissProt/SPupdate/PIR data base (See Table IV of Takahashi et al., *J. Biol. Chem.*, 272(6):3437-43 (1997)). Numbers indicate the amino acid positions within each sequence. Conservative substitutions are indicated by (+). The data of amadoriases correspond to the N-terminal sequences obtained in Takahashi et al., *J. Biol. Chem.*, 272(6):3437-43 (1997).

Table 2. Amino acid sequence homology between the N-terminal sequence of amadoriase Ia, amadoriase Ib, amadoriase Ic and amadoriase II

Protein	Sequences with residue nos.	SEQ ID NO
Amadoriases Ia	<sup>1</sup> AP SIL STESS I (C/T) V I G A G T W G <sup>20</sup>	SEQ ID NO:7
Amadoriase Ib	<sup>1</sup> AP SIL STESS I I V I G A G T W G <sup>20</sup>	SEQ ID NO:8
Amadoriase Ic	<sup>1</sup> ST ESS I I V I G A G T W G (C) (S) T A L <sup>20</sup>	SEQ ID NO:9
Amadoriase II	<sup>1</sup> A V T K S S S L L I V G A G T W G T S T <sup>20</sup>	SEQ ID NO:10

[0042] Other amadoriases, *e.g.*, amadoriases disclosed in GenBank Accession No. U82830 (Takahashi et al., *J. Biol. Chem.*, 272(19):12505-12507 (1997) and amadoriases disclosed U.S. Patent No. 6,127,138 can also be used. A functional fragment or a derivative of an amadoriase that still substantially retain its enzymatic activity catalyzing the oxidative deglycation of Amadori products to yield corresponding amino acids, glucosone, and H<sub>2</sub>O<sub>2</sub> can also be used.

[0043] Normally, a functional fragment or a derivative of an amadoriase retain at least 50% of its enzymatic activity. Preferably, a functional fragment or a derivative of an amadoriase retain at least 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100% of its enzymatic activity.

[0044] Assays for enzymatic activities of amadoriases are known in the art (See e.g., Takahashi et al., *J. Biol. Chem.*, 272(6):3437-43 (1997) and U.S. Patent No. 6,127,138). Four exemplary assays for enzymatic activities of amadoriases are disclosed in Takahashi et al., *J. Biol. Chem.*, 272(6):3437-43 (1997).

#### *Glucosone Formation*

[0045] In this assay, the enzyme activity is monitored by the release of glucosone measured by a colorimetric reaction with OPD using fructosyl propylamine as a substrate. This assay is based on the end point measurement of glucosone formed after 120 min of reaction time. The reaction mixture contains 20 mM sodium phosphate, pH 7.4, 10 mM OPD, 10 mM fructosyl propylamine, and enzyme protein in a final volume of 1 ml. After incubation at 37°C for 2 h, the absorbance at 320 nm is measured. The reaction is linear to 240 min in a dose-dependent manner under these conditions. One unit of enzyme activity is defined as the amount of the enzyme that produces 1  $\mu$ mol of glucosone/min. Synthesized glucosone is used as a standard.

#### *Free Amine Assay*

[0046] To assay the release of free amine, fluorescence is measured after reaction with fluorescamine. Twenty-five (25)  $\mu$ l of a solution of pure enzyme or enzyme-rich fraction, 15  $\mu$ l of 20% fructosyl propylamine in water, and 250  $\mu$ l of PBS are incubated at 37°C for different times as indicated. The reaction is stopped by filtration through a Microcon-10 (Amicon, Beverly, MA) at 4 C. One (1)  $\mu$ l of the pure or 1:10 diluted filtrate is added to 1.5 ml of 50 mM phosphate buffer pH 8.0. Under vigorous vortexing 0.5 ml of 0.03% fluorescamine in dioxane is rapidly added. After 5 min fluorescence is measured ( $\lambda_{ex}$  = 390 nm,  $\lambda_{em}$  = 475 nm). A standard plot is made with 6-150 ng of propylamine.

#### *H<sub>2</sub>O<sub>2</sub> Assay*

[0047] Hydrogen peroxide is quantitated by the quinone dye assay according to Sakai et al., *Biosci. Biotech. Biochem.*, 59:487-491 (1995). The reaction mixture contains 20 mM Tris-HCl, pH 8.0, 1.5 mM 4-aminoantipyrine, 2.0 mM phenol, 2.0 units of peroxidase, 10 mM fructosyl propylamine, and enzyme protein in a total volume of 1 ml. Production of the H<sub>2</sub>O<sub>2</sub> is monitored by the formation of a quinone dye following the absorbance at 505 nm ( $\epsilon$

$= 5.13 \times 10^3$ ). The production of 0.5  $\mu\text{mol}$  of quinone dye corresponds to the formation of 1.0  $\mu\text{mol}$  of  $\text{H}_2\text{O}_2$ .

### *Oxygen Consumption*

**[0048]** Oxygen consumption is determined with a YSI-Beckman glucometer II equipped with a Clarke type oxygen electrode as described in Gerhardinger, et al., *J. Biol. Chem.*, 270:218-224 (1995). Briefly, enzyme (50  $\mu\text{l}$ ) is added to the chamber containing 750  $\mu\text{l}$  of PBS and 650  $\mu\text{l}$  of water. The reaction is started by addition of 50  $\mu\text{l}$  of 300 mM fructosyl propylamine (final concentration 10 mM).

**[0049]** In another example, the amadoriase has at least 40% identity to the amino acid sequence set forth in SEQ ID NO:3  
(AVTKSSSLIVGAGTWGTSTALHLARRGYTNVTVLDPYPVPSAISAGNDVNKVISSGQ  
YSNNKDEIEVNEILAEAFNGWKNDPLFKPYHDTGLLMSACSQEGLDRLGVRVRPG  
EDPNLVELTRPEQFRKLAPEGVLQGDFFGWKGYFARSGAGWAHARNALVAAAREAQ  
RMGVKFVTGTPQGRVVTLFENNDVKGAVTGDGKIWRAERTFLCAGASAGQFLDFK  
NQLRPTAWTLVHIALKPEERALYKNIPVIFNIERGFFFEPEERGEIKICDEHPGYTNMV  
QSADGTMMSIPFEKTQIPKEAETRVRALLKETMPQLADRPFSFARICWCADTANREFLI  
DRHPQYHSLVLGCGASGRGFKYLPSIGNLIVDAMEGKVPQKIHNIKWNPDIANRN  
WRDTLGRFGGPNRVMDFHDVKEWTNVQYRDISKL), in which the percentage identity is determined over an amino acid sequence of identical size to the amino acid sequence set forth in SEQ ID NO:3. Preferably, the amadoriase has at least 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO:3, in which the percentage identity is determined over an amino acid sequence of identical size to the amino acid sequence set forth in SEQ ID NO:3. Also preferably, the amadoriase binds to an antibody that specifically binds to an amino acid sequence set forth in SEQ ID NO:3. Also preferably, the amadoriase comprises the amino acid sequence set forth in SEQ ID NO:3.

**[0050]** The first and second peptidyl fragments can be linked via any suitable linkage. For example, the first and second peptidyl fragments can be linked via a cleavable linkage.

**[0051]** The isolated chimeric protein can further comprise, at its C-terminus, a third peptidyl fragment comprising a second bacterial leader sequence from about 5 to about 30 amino acid residues. Any suitable bacterial leader sequences, including the ones described above, can be used.

**[0052]** In one example, the second bacterial leader sequence is a leader sequence of an *E.coli* protein. in another example, the second bacterial leader sequence has at least 40% identity to the amino acid sequence set forth in SEQ ID NO:4 (KGELEGLPIPNNLLRTG), in which the percentage identity is determined over an amino acid sequence of identical size to the amino acid sequence set forth in SEQ ID NO:4. Preferably, the second bacterial leader sequence has at least 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100% identity to the amino acid sequence set forth in SEQ ID NO:4, in which the percentage identity is determined over an amino acid sequence of identical size to the amino acid sequence set forth in SEQ ID NO:4. Also preferably, the second bacterial leader sequence binds to an antibody that specifically binds to an amino acid sequence set forth in SEQ ID NO:4. Also preferably, the second bacterial leader sequence comprises the amino acid sequence set forth in SEQ ID NO:4.

**[0053]** The third peptidyl fragment can have an suitable length. For example, the third peptidyl fragment comprises about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acid residues. Preferably, the third peptidyl fragment comprises about 20 amino acid residues.

**[0054]** The isolated chimeric protein of can further comprise, at its C-terminus, a third peptidyl fragment comprising a peptide tag. Any suitable tag can be used. For example, the tag can be FLAG, HA, HA1, c-Myc, 6-His, AU1, EE, T7, 4A6,  $\epsilon$ , B, gE and Ty1 tag (See Table 3).

Table 3. Exemplary epitope tag systems

Epitope	Peptide	SEQ ID	Antibody	Reference
FLAG	AspTyrLysAspAspAspLys	11	4E11	Prickett <sup>1</sup>
HA	TyrProTyrAspValProAspTyrAla	12	12Ca5	Xie <sup>2</sup>
HA1	CysGlnAspLeuProGlyAsnAspAsnSerThr	13	mouse MAb	Nagelkerken <sup>3</sup>
c-Myc	GluGlnLysLeulleSerGluGluAspLeu	14	9E10	Xie <sup>2</sup>
6-His	HisHisHisHisHisHis	15	BAbCO*	
AU1	AspThrTyrArgTyrIle	16	BAbCO	
EE	GluTyrMetProMetGlu	17	anti-EE	Tolbert <sup>4</sup>
T7	AlaSerMetThrGlyGlyGlnGlnMetGlyArg	18	Invitrogen	Chen <sup>5</sup> Tseng <sup>6</sup>
4A6	SerPheProGlnPheLysProGlnGluIle	19	4A6	Rudiger <sup>7</sup>
$\epsilon$	LysGlyPheSerTyrPheGlyGluAspLeuMetPro	20	anti-PKC $\epsilon$	Olah <sup>8</sup>
B	GlnTyrProAlaLeuThr	21	D11, F10	Wang <sup>9</sup>
gE	GlnArgGlnTyrGlyAspValPheLysGlyAsp	22	3B3	Grose <sup>10</sup>
Ty1	GluValHisThrAsnGlnAspProLeuAsp	23	BB2, TYG5	Bastin <sup>11</sup>

1. Prickett, *et al.*, *BioTechniques*, 7(6):580-584 (1989)
2. Xie, *et al.*, *Endocrinology*, 139(11):4563-4567 (1998)
3. Nagelkerke, *et al.*, *Electrophoresis*, 18:2694-2698 (1997)
4. Tolbert and Lamah, *J. Neurochem.*, 70:113-119 (1998)
5. Chen and Katz, *BioTechniques*, 25(1):22-24 (1998)
6. Tseng and Verma, *Gene*, 169:287-288 (1996)
7. Rudiger, *et al.*, *BioTechniques*, 23(1):96-97 (1997)
8. Olah, *et al.*, *Biochem.*, 221:94-102 (1994)
9. Wang, *et al.*, *Gene*, 169(1):53-58 (1996)
10. Grose, U.S. Patent No. 5,710,248
11. Bastin, *et al.*, *Mol. Biochem. Parasitology*, 77:235-239 (1996) Invitrogen, Sigma, Santa Cruz Biotech

[0055] In an example, the isolated chimeric protein comprises the amino acid sequence set forth in SEQ ID NO:5

(MGGSGDDDDLALAVTKSSSLIVGAGTWGTSTALHLARRGYTNVTVLDPYPVPSAIS  
AGNDVNKVISSGQYSNNKDEIEVNEILAEAFNGWKNDPLFKPYYHDTGLLMSACSQ  
EGLDRLGVRVRPGEDPNLVELTRPEQFRKLAPEGVLQGDFFGWKGYFARSGAGWAH  
ARNALVAAAREAQRMGVKFVTGTPQGRVVTILFENNDVKGAVTGDGKIWRAERTFL  
CAGASAGQFLDFKNQLRPTAWTLVHIALKPEERALYKNIPVIFNIERGFFFEPEDEERGEI  
KICDEHPGYTNMVQSADGTMMISPFKQTQIPKEAETRVRALLKETMPQLADRPFSFARI  
CWCADTANREFLIDRHPQYHSLVLGCGASGRGFKYLPISGNLIVDAMEGKVPQKIH  
ELIKWNPDIAANRNWRDTLGRFGGPNRVMDFHDVKEWTNVQYRDISKLKGELEGLPIPN  
PLLRTGHHHHHH).

[0056] In another aspect, the present invention is directed to an isolated nucleic acid comprising a nucleotide sequence encoding a chimeric protein, which chimeric protein comprises, from N-terminus to C-terminus: a) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and b) a second peptidyl fragment comprising an amadoriase.

[0057] In one example, the isolated nucleic acid comprises a nucleotide sequence encoding the chimeric protein comprising the amino acid sequence set forth in SEQ ID NO:5. In another example, the isolated nucleic acid comprises a nucleotide sequence set forth in SEQ ID NO:6

(ATGGGAGGTTCGGGTGACGATGATGACCTGGCTCTCGCCGTCACCTAAGTCATCAT  
CTCTCCTGATCGTTGGTGCCGGGACTTGGGGCACCTCAACGGCTCTGCACCTCGCG  
CGCCGCGGATATACCAACGTTACCGTGCTGGACCCCTATCCTGTCCCTAGCGCCAT  
CTCCGCCGGAAACGACGTGAACAAAGTCATTAGCAGTGGCCAATATTCGAATAAC

AAAGACGAAATCGAAGTGAATGAGATCTTGGCGGAAGAGGCGTTTAACGGTTGGA  
AGAACGACCCGCTTTTCAAACCGTATTATCATGATACGGGCCTGCTGATGTCTGCT  
TGCTCGCAGGAGGGCCTGGATCGCCTGGGCGTCCGGGTACGTCCGGGCGAGGATC  
CTAATCTGGTGGAACCTACCCGCCCGGAGCAATTTTCGTAAACTGGCCCCGGAAGG  
CGTGTTGCAAGGTGATTTTCCGGGTGGAAAGGGTACTTTGCGCGTTCCGGCGCTG  
GCTGGGCACATGCAAGGAATGCCTTAGTGGCAGCAGCACGCGAAGCACAGCGCAT  
GGGTGTAAAATTTGTTACTGGCACCCCGCAGGGTCGTGTAGTCACGTTAATCTTTG  
AAAATAACGATGTAAAAGGTGCCGTTACGGGCGATGGCAAAATTTGGAGAGCGGA  
ACGTACATTCTGTGTGCTGGGGCTAGCGCGGGTCAGTTCCTAGATTTCAAGAATC  
AACTTCGACCAACCGCTTGGACCCTGGTACACATTGCGTTAAAACCGGAAGAACG  
TGCCTTGTACAAAAATATACCGGTTATCTTTAACATCGAACGGGGGTTTTTCTTTG  
AACCCGATGAGGAGCGCGGTGAGATTAATAATATGCGATGAACACCCGGGCTACAC  
AAATATGGTCCAGAGTGCAGACGGCACGATGATGAGCATTCCGTTGAAAAAACC  
CAGATTCCAAAAGAAGCCGAAACGCGCGTTCGGGCCCTGCTGAAAGAGACAATGC  
CCCAGCTGGCAGACCGTCCATTCAGCTTCGCACGCATTTGCTGGTGTGCCGATACC  
GCGAATCGCGAATTCCTGATAGATCGACATCCGCAGTACCACAGTCTTGTGTTGGG  
CTGTGGTGCGAGCGGAAGAGGGTTTAAATATCTGCCTTCTATTGGGAATCTCATTG  
TTGACGCGATGGAAGGTAAAGTGCCGCAAAAAATTACGAATTAATCAAGTGGA  
CCCGGACATTGCGGCGAACCGTAACTGGCGTGATACTCTGGGGCGTTTTGGCGGTC  
CAAATCGTGTGATGGATTTTCATGATGTGAAGGAATGGACCAATGTTTCAGTATCGT  
GATATTTCCAAGCTGAAAGGAGAGTTGGAAGGTaaGCCAATCCCTAACCCGTTACT  
GCGCACAGGCCATCACCATCATCATCATTA).

**[0058]** In still another example, the isolated nucleic acid comprising a nucleotide sequence complementary to the nucleotide sequence encoding a chimeric protein, which chimeric protein comprises, from N-terminus to C-terminus: a) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and b) a second peptidyl fragment comprising an amadoriase.

**[0059]** A recombinant cell containing the nucleic acid, or a complementary strand thereof, encoding a chimeric protein, which chimeric protein comprises, from N-terminus to C-terminus: a) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and b) a second peptidyl fragment comprising an amadoriase, is contemplated.

[0060] A method of producing a chimeric protein is also contemplated, which method comprising growing a recombinant cell containing the nucleic acid encoding a chimeric protein, which chimeric protein comprises, from N-terminus to C-terminus: a) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and b) a second peptidyl fragment comprising an amadoriase, such that the encoded chimeric protein is expressed by the cell, and recovering the expressed chimeric protein. The product of the method is further contemplated.

[0061] The chimeric proteins and the nucleic acids encoding the chimeric proteins can be prepared by any suitable methods, *e.g.*, chemical synthesis, recombinant production or a combination thereof (*See e.g.*, Current Protocols in Molecular Biology, Ausubel, et al. eds., John Wiley & Sons, Inc. (2000) and Sambrook, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory press, (1989)).

### **C. Methods and kits for assaying for a glycated protein using a chimeric protein**

[0062] In still another aspect, the present invention is directed to a method for assaying for a glycated protein in a sample, which method comprises: a) contacting a sample to be assayed with a protease to generate a glycated peptide or a glycated amino acid from a glycated protein, if contained in said sample; b) contacting said generated glycated peptide or glycated amino acid with a chimeric protein comprising, from N-terminus to C-terminus: i) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and ii) a second peptidyl fragment comprising an amadoriase, to oxidize said glycated peptide or glycated amino acid; and c) assessing oxidation of said glycated peptide or glycated amino acid by said chimeric protein to determine the presence and/or amount of said glycated protein in said sample.

[0063] The present methods can be used to assay any suitable sample. Preferably, the sample is a blood sample, *e.g.*, a plasma, serum, red blood cell or whole blood sample.

[0064] The present methods can be used to assay any suitable glycated proteins. Preferably, the glycated protein to be assayed is glycoalbumin or glycohemoglobin.

[0065] Any suitable protease can be used in the present methods. Either an endo-type protease or an exo-type protease can be used. Exemplary endo-type proteases include trypsin,  $\alpha$ -chymotrypsin, subtilisin, proteinase K, papain, cathepsin B, pepsin, thermolysin, protease XVII, protease XXI, lysyl-endopeptidase, prolether and bromelain F. Exemplary exo-type



proteases include an aminopeptidase or a carboxypeptidase. In one example, the protease is proteinase K, pronase E, ananase, thermolysin, subtilisin or cow pancreas proteases.

[0066] The protease can be used to generate a glycosylated peptide of any suitable size. For example, the protease can be used to generate a glycosylated peptide from about 2 to about 30 amino acid residues. In another example, the protease is used to generate glycosylated glycine, glycosylated valine or glycosylated lysine residue or a glycosylated peptide comprising glycosylated glycine, glycosylated valine or glycosylated lysine residue.

[0067] Any suitable chimeric proteins, including the ones described in the above Section B, can be used in the present methods. In one example, the chimeric protein comprises the amino acid sequence set forth in SEQ ID NO:5. In another example, the chimeric protein is encoded by the nucleotide sequence set forth in SEQ ID NO:6.

[0068] The oxidation of the glycosylated peptide or glycosylated amino acid can be assessed by any suitable methods. For example, the oxidation of the glycosylated peptide or glycosylated amino acid can be assessed by assessing consumption of the glycosylated peptide or glycosylated amino acid,  $H_2O$  or  $O_2$  in the oxidation reaction or the formation of the oxidized glucose (glucosone),  $H_2O_2$  or the amino acid in the oxidation reaction.

[0069] The  $O_2$  consumption can be assessed by any suitable methods. For example, the  $O_2$  consumption can be assessed by an oxygen electrode.

[0070] The  $H_2O_2$  formation can be assessed by any suitable methods. For example, the  $H_2O_2$  formation can be assessed by a peroxidase. Any peroxidase can be used in the present methods. More preferably, a horseradish peroxidase is used. For example, the horseradish peroxidases with the following GenBank accession Nos. can be used: E01651; D90116 (prxC3 gene); D90115 (prxC2 gene); J05552 (Synthetic isoenzyme C(HRP-C)); S14268 (neutral); OPRHC (C1 precursor); S00627 (C1C precursor); JH0150 (C3 precursor); S00626 (C1B precursor); JH0149 (C2 precursor); CAA00083 (*Armoracia rusticana*); and AAA72223 (synthetic horseradish peroxidase isoenzyme C (HRP-C)). In another example, the  $H_2O_2$  formation can be assessed by a peroxidase and Trinder reaction. The glycosylated peptide or glycosylated amino acid can be contacted with the chimeric protein and the peroxidase sequentially or simultaneously.

[0071] The glucosone formation can be assessed by any suitable methods. For example, the glucosone formation can be assessed by a glucose oxidase. Any suitable glucose oxidase can be used. For example, glucose oxidases encoded by the nucleotide sequences with the following GenBank accession Nos. can be used: AF012277 (*Penicillium amagasakiense*);

U56240 (*Talaromyces flavus*); X16061 (*Aspergillus niger* gox gene); X56443 (*A.niger* god gene); J05242 (*A.niger*); AF012277 (*Penicillium amagasakiense*); U56240 (*Talaromyces flavus*); X16061 (*Aspergillus niger* gox gene); X56443 (*A.niger* god gene); J05242 (*A.niger* glucose). Preferably, the nucleotide sequences with the GenBank accession No. J05242 (*See also* Frederick, *et al.*, *J. Biol. Chem.*, 265(7):3793-802 (1990)) and the nucleotide sequences described in U.S. Patent No. 5,879,921 can be used in obtaining nucleic acid encoding glucose oxidase.

**[0072]** In another example, the glucosone formation can be assessed by a combination of glucose 6-phosphate dehydrogenase and hexokinase. Any suitable glucose 6-phosphate dehydrogenase can be used. For example, glucose 6-phosphate dehydrogenase disclosed in the following patents and patent applications can be used: WO 03/042389, WO 01/98472, WO 93/06125, and U.S. Patent Nos. 6,127,345, 6,069,297, 5,856,104, 5,308,770, 5,244,796, 5,229,286, 5,137,821 and 4,847,195. Any suitable hexokinase can be used. For example, hexokinase disclosed in the following patents and patent applications can be used: WO 02/20795, US2002/009779, WO 01/90378, WO 01/90325, WO 01/68694, WO 01/47968 and U.S. Patent No 5,948,665.

**[0073]** If desirable, the protease can be inactivated before or current with the contact between the glycated peptide or glycated amino acid and the chimeric protein. The protease can be inactivated by any suitable methods. For example, the protease can be inactivated by a heat treatment or an inhibitor of the protease.

**[0074]** If desirable, interference of the assay can be countered. For example, ascorbate interference can be countered using a copper (II) compound, a cholic acid or a bathophenanthroline disulphonic acid or a mixture thereof. Bilirubin interference can be countered using a ferrocyanide salt.

**[0075]** The present methods can be used for any suitable purpose. Preferably, the method used in the prognosis or diagnosis of a disease or disorder, *e.g.*, diabetes.

**[0076]** In yet another aspect, the present invention is directed to a kit for assaying for a glycated protein in a sample, which kit comprises: a) a protease to generate glycated peptide or glycated amino acid from a glycated protein, if contained in a sample; b) a chimeric protein comprising, from N-terminus to C-terminus: i) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and ii) a second peptidyl fragment comprising an amadoriase, to oxidize said glycated peptide or glycated amino acid; and c) means for assessing oxidation of said glycated peptide or glycated amino acid by said

chimeric protein to determine the presence and/or amount of said glycosylated protein in said sample.

[0077] Any suitable means can be included in the present kits. For example, the means for assessing oxidation of said glycosylated peptide or glycosylated amino acid by said chimeric protein can comprise a peroxidase. Preferably, the chimeric protein and the peroxidase are formulated in a single composition.

#### **D. Methods and kits for assaying for a glycosylated protein using proteinase K and an amadoriase**

[0078] In yet another aspect, the present invention is directed to a method for assaying for a glycosylated protein in a sample, which method comprises: a) contacting a sample to be assayed with a proteinase K to generate a glycosylated peptide or a glycosylated amino acid from a glycosylated protein, if contained in said sample; b) contacting said generated glycosylated peptide or glycosylated amino acid with an amadoriase to oxidize said glycosylated peptide or glycosylated amino acid; and c) assessing oxidation of said glycosylated peptide or glycosylated amino acid by said amadoriase to determine the presence and/or amount of said glycosylated protein in said sample.

[0079] The present methods can be used to assay any suitable sample. Preferably, the sample is a blood sample, *e.g.*, a plasma, serum, red blood cell or whole blood sample.

[0080] The present methods can be used to assay any suitable glycosylated proteins. Preferably, the glycosylated protein to be assayed is glycoalbumin or glycohemoglobin.

[0081] Any suitable amadoriase, including the ones described in the above Sections B and C, can be used in the present methods. For example, the amadoriase can comprise a chimeric protein, which chimeric protein comprises, from N-terminus to C-terminus: a) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and b) a second peptidyl fragment comprising an amadoriase. Preferably, the chimeric protein comprises the amino acid sequence set forth in SEQ ID NO:5. Also preferably, the chimeric protein is encoded by the nucleotide sequence set forth in SEQ ID NO:6.

[0082] The oxidation of the glycosylated peptide or glycosylated amino acid can be assessed by any suitable methods. For example, the oxidation of the glycosylated peptide or glycosylated amino acid can be assessed by assessing consumption of the glycosylated peptide or glycosylated amino acid, H<sub>2</sub>O or O<sub>2</sub> in the oxidation reaction or the formation of the oxidized glucose (glucosone), H<sub>2</sub>O<sub>2</sub> or the amino acid in the oxidation reaction.

[0083] The O<sub>2</sub> consumption can be assessed by any suitable methods. For example, the O<sub>2</sub> consumption can be assessed by an oxygen electrode.

[0084] The H<sub>2</sub>O<sub>2</sub> formation can be assessed by any suitable methods. For example, the H<sub>2</sub>O<sub>2</sub> formation can be assessed by a peroxidase. Any peroxidase, including the ones described in the above Sections C, can be used in the present methods. More preferably, a horseradish peroxidase is used. In another example, the H<sub>2</sub>O<sub>2</sub> formation can be assessed by a peroxidase and Trinder reaction. The glycated peptide or glycated amino acid can be contacted with the chimeric protein and the peroxidase sequentially or simultaneously.

[0085] The glucosone formation can be assessed by any suitable methods. For example, the glucosone formation can be assessed by a glucose oxidase. Any suitable glucose oxidase, including the ones described in the above Sections C, can be used.

[0086] In another example, the glucosone formation can be assessed by a combination of glucose 6-phosphate dehydrogenase and hexokinase. Any suitable glucose 6-phosphate dehydrogenase, including the ones described in the above Sections C, can be used. Any suitable hexokinase, including the ones described in the above Sections C, can be used.

[0087] Any suitable proteinase K can be used in the present methods. For example, proteinase K disclosed in the following patents and patent applications can be used: WO 02/072634, WO 02/064760, WO 96/28556, and U.S. Patent Nos. 6451574 and 5344770. Preferably, proteinase K from *Tritirachium album* is used (See e.g., Sigma-Aldrich Catalog No. 82452).

[0088] If desirable, the proteinase K can be inactivated before or concurrent with the contact between the glycated peptide or glycated amino acid and the amadoriase. For example, the proteinase K can be inactivated by a heat treatment or an inhibitor of the proteinase K.

[0089] If desirable, interference of the assay can be countered. For example, ascorbate interference can be countered using a copper (II) compound, a cholic acid or a bathophenanthroline disulphonic acid or a mixture thereof. Bilirubin interference can be countered using a ferrocyanide salt.

[0090] The present methods can be used for any suitable purpose. Preferably, the method used in the prognosis or diagnosis of a disease or disorder, e.g., diabetes.

[0091] In yet another aspect, the present invention is directed to a kit for assaying for a glycated protein in a sample, which kit comprises: a) a proteinase K to generate a glycated peptide or a glycated amino acid from a glycated protein, if contained in said sample; b) an amadoriase to oxidize said glycated peptide or glycated amino acid; and c) means for assessing

oxidation of said glycated peptide or glycated amino acid by said amadoriase to determine the presence and/or amount of said glycated protein in said sample.

[0092] Any suitable means can be included in the present kits. For example, the means for assessing oxidation of said glycated peptide or glycated amino acid by said chimeric protein can comprise a peroxidase. Preferably, the chimeric protein and the peroxidase are formulated in a single composition.

[0093] Any suitable amadoriase, including the ones described in the above Sections B and C, can be used in the present kits. For example, the amadoriase can comprise a chimeric protein, which chimeric protein comprises, from N-terminus to C-terminus: a) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and b) a second peptidyl fragment comprising an amadoriase. Preferably, the chimeric protein comprises the amino acid sequence set forth in SEQ ID NO:5. Also preferably, the chimeric protein is encoded by the nucleotide sequence set forth in SEQ ID NO:6.

## E. Examples

### Example 1. Glycated Serum Protein Enzymatic Assay Kit

[0094] **Intended Use.** The exemplary assay kit is for determination of glycated serum proteins (fructosamine) in human serum. Fructosamine is formed due to a non-enzymatic Maillard reaction between glucose and amino acid residues of proteins. In diabetic patients, elevated blood glucose levels correlate with increased fructosamine formation. Fructosamine is a medium term indicator of diabetic control (2-3 weeks).

[0095] **Assay Principle.** The exemplary enzymatic assay for glycated serum proteins (GSP) uses Proteinase K to digest GSP into low molecular weight glycated protein fragments (GPF), and uses Diazyme's specific fructosaminase<sup>TM</sup>, a microorganism originated amadoriase to catalyze the oxidative degradation of Amadori product GPF to yield PF or amino acids, glucosone and H<sub>2</sub>O<sub>2</sub>. The H<sub>2</sub>O<sub>2</sub> released is measured by a colorimetric Trinder end-point reaction. The absorbance at 550 nm is proportional to the concentration of glycated serum proteins (GSP).





Table 4. Reagent Table

Reagent 1 (R1) Lyophilized 2 x 20 mL	Proteinase K, buffer
Reagent 2 (R2) Lyophilized 2 x 5mL	Fructosaminase <sup>TM</sup> , HRP, buffer

**[0096] Test Samples.** Use fresh patient serum or EDTA treated plasma samples.

Plasma should be separated from cells immediately after collection. Samples can be stored at 4°C for 2 weeks or up to 4 weeks when frozen.

**[0097] Reconstitution.** One vial of Reagents 1 is reconstituted with 20 mL of distilled water. Mix gently by inversion and then allow to stand for a minimum of 10 min at room temperature before use. The reconstituted R1 is stable for 4 weeks at 4°C. One vial of Reagent 2 is reconstituted with 5 mL of distilled water. Mix gently by inversion and then allow to stand at room temperature for minimum of 10 min before use. The reconstituted R2 is stable for 6 weeks at 4°C.

**[0098] Assay Procedure**

1. Pre-warm reconstituted R1 and R2 at room temperature.
2. Instrumental parameters.

Wavelength: 550nm; reference 700 nm

Cuvette: 1 cm light path


Temperature: 37°C

3. Add 200 µL of the reconstituted R1 and 50 µL of sample or calibrator into cuvette.

Mix and incubate for 5 min. Read absorbance at 550 nm as A<sub>1</sub>.

4. Add 50  $\mu$ L of the reconstituted R2, mix and incubate for further 5 min and then read the absorbance at 550 nm as  $A_2$ .

5. Reagent blank absorbance is read by using 50  $\mu$ L of  $H_2O$  instead of sample or calibrator.



#### [0099] Calculation

$$\Delta A = A_2 - A_1$$

Concentration of glycated serum proteins (fructosamine) in sample:

$$\text{Fructosamine } (\mu\text{mole/L}) = \frac{\Delta A_{\text{sample}} - \Delta A_{\text{blank}}}{\Delta A_{\text{standard}} - \Delta A_{\text{blank}}} \times \text{Conc. of calibrator}$$

[0100] **Normal values.** Adults (20-60 years) have a normal range of 122-285  $\mu$ mol/L. Each laboratory should establish an expected range with a set of standards.

[0101] **Linearity and Sensitivity.** The assay is linear up to 1200  $\mu$ mol/L and is sensitive at 30  $\mu$ mol/L. The Diazyme Glycated Serum Protein (fructosamine) assay is precise with a mean inter-assay CV of <3% and mean intra assay CV of <2%. Assay data showed excellent correlation with the alternative fructosamine measurement method with  $r^2 = 0.99$ .

[0102] **Interferences.** The following analyte concentrations were not found to affect the assay:

Ascorbic acid (4 mg/dL)

Bilirubin (2 mg/dL)

Glucose (1200mg/dL)

Hemoglobin (100mg/dL)

Triglycerides (250 mg/dL)

Uric acid (15 mg/dL)

[0103]        **Calibration.** Fructosamine Calibrator (Cat. No. DZ112A-S) is required for calibration.

[0104]        **Quality Control.** Fructosamine Controls (low and high) (Cat. No. DZ112A-C1 and DZ112A-C3) are recommended to use as control sera. One control (low or high) should be tested after every 30 samples. Values should fall within a specific range. If these values fall outside the range and repetition excludes error, the following steps should be taken:

1. Check instrument settings and light source;
2. Check reaction temperature;
3. Check expiry date of kit and contents; and
4. Check the quality of the water used for reagents reconstitution.

[0105]        **References**

Armbruster DA, Fructosamine: Structure, Analysis and Clinical Usefulness. *Clin. Chem.* 1987; 33 (12): 2153-2163.

Kouzuma, T. *et al.* An enzymatic method for the measurement of glycosylated albumin in biological samples. *Clin. Chim. Acta* 2002; 324: 61-71.

Example 2. Glycated Serum Protein Assay Precision and Linearity

**METHOD COMPARISON**

[0106]        Determined by running 2 replicates of a set of random samples using both Diazyme GSP kit and Randox Fructosamine kit in one run. The analytical performance characteristics determined by Diazyme GSP kit were comparable to those observed with Randox Fructosamine kit when assays were performed under the conditions as described in the Example 1 (*See also* Figure 1).

**ASSAY LINEARITY**

[0107]        Determined by running 2 replicates of a set of series diluted serum samples in one run. The assay is linear from 40-856  $\mu\text{mole/L}$  (*See* Figure 2).

**INTERFERENCE**

[0108]        Determined by running 3 replicates each of a control sample in the absence and presence of various potential interference substances at indicated concentrations (*See* the following Table 5).



Table 5. Interference analysis

Interfering substances	Interfering substance concentration	% Interference
Ascorbic Acid	4 mg/dL	-0.3
Bilirubin	2 mg/dL	-0.6
Glucose	1200mg/dL	-0.6
Hemoglobin	100 mg/dL	-4.4
Triglycerol	250mg/dL	1.2
Uric Acid	15mg/dL	5.3

Example 3. Assay for Glycated Hemoglobin HbA1cA. Glycated Valine Measurement:

[0109] 1. Mix 10ul 170mM Glycated Valine (G-Valine) (This value was assumed all valine was converted to G-Valine in the cooking procedure.) with 300ul R1 (80mMCHES, 30mMOPS, 0.9%BRIJ). This mixture serves as sample stock solution (GVR1).

[0110] 2. Set spectrometer wavelength at 726nm, temperature at 37°C. Pipette 150ul R2 (30mMMES, 1mM $\text{CaCl}_2$ , 2mMWST-3, 1570U/ml Proteinase K) to a cuvette, add 0ul, 2.5ul, 5ul, 10ul, 15ul, 20ul above GVR1 respectively for dose response, make up the sample volume to 20 ul with  $\text{H}_2\text{O}$  in R1, incubate for 5min, get the first O.D. reading, then add 30ul R3 (0.08mMDA-64, 240mMTris, 180U/ml HRP, 20U/ml FAOD), incubate for 3 min, get the second O.D. reading. Calculate the O.D. difference between these two readings, using 20ul  $\text{H}_2\text{O}$  in R1 as control. Figures 3 and 4 show the dose-dependent reaction with fructosyl-valine.

B. Glycated Hemoglobin Measurement:

[0111] 1. Mix 10ul high level Glycated Hemoglobin (G-hg(HHg)), 10ul mid level G-hg(MHg), 10ul normal level G-hg (NMHg) respectively with 300ul R1.

[0112] 2. Set spectrometer wavelength at 570nm, temperature at 37°C. Pipette 150ul R2 to cuvette, add 20 ul above Hg in R1 as sample, read the O.D. after 4 min incubation, using  $\text{H}_2\text{O}$  in R1 as control. This O.D. reading gives the relative Hg concentration.

[0113] 3. Change the spectrometer wavelength to 726nm, get the first O.D. reading, add 30ul R3, incubate for 5min, get the second O.D. reading. Calculate the O.D. difference between these two readings. Normalize these O.D. differences of the three samples with their Hg concentrations. Figure 5 shows the dose-dependent signal with patient hemoglobin digested with a proteinase (5 min. digestion).

**[0114]** The above examples are included for illustrative purposes only and are not intended to limit the scope of the invention. Many variations to those described above are possible. Since modifications and variations to the examples described above will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

**What is claimed is:**

1. An isolated chimeric protein, which chimeric protein comprises, from N-terminus to C-terminus:

- a) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and
- b) a second peptidyl fragment comprising an amadoriase.

2. The isolated chimeric protein of claim 1, wherein the bacterial leader sequence is a leader sequence of an *E.coli* protein.

3. The isolated chimeric protein of claim 1, wherein the leader sequence has at least 40% identity to the amino acid sequence set forth in SEQ ID NO:1 (MGGSGDDDDLAL), in which the percentage identity is determined over an amino acid sequence of identical size to the amino acid sequence set forth in SEQ ID NO:1.

4. The isolated chimeric protein of claim 1, wherein the leader sequence binds to an antibody that specifically binds to an amino acid sequence set forth in SEQ ID NO:1.

5. The isolated chimeric protein of claim 1, wherein the leader sequence comprises the amino acid sequence set forth in SEQ ID NO:1.

6. The isolated chimeric protein of claim 1, wherein the first peptidyl fragment comprises about 20 amino acid residues.

7. The isolated chimeric protein of claim 1, wherein the amadoriase is of *Aspergillus* sp. origin.

8. The isolated chimeric protein of claim 7, wherein the amadoriase uses FAD as a cofactor.

9. The isolated chimeric protein of claim 8, wherein the amadoriase has a FAD cofactor-binding consensus sequence Gly-X-Gly-X-X-Gly (SEQ ID NO:2), X being any amino acid residue.

10. The isolated chimeric protein of claim 7, wherein the amadoriase is selected from the group consisting of amadoriase Ia, amadoriase Ib, amadoriase Ic and amadoriase II.

11. The isolated chimeric protein of claim 1, wherein the amadoriase has at least 40% identity to the amino acid sequence set forth in SEQ ID NO:3  
(AVTKSSSLIVGAGTWGTSTALHLARRGYTNVTVLDPYPVPSAISAGNDVNKVISSGQ  
YSNNKDEIEVNEILAEAFNGWKNDPLFKPYHDTGLLMSACSQEGLDRLGVRVRPG  
EDPNLVELTRPEQFRKLAPEGVLQGDFFGWKGYFARSGAGWAHARNALVAAAREAQ  
RMGVK FVTGTPQGRVVT LIFENNDVKGAVTGDGKIWRAERTFLCAGASAGQFLDFK  
NQLRPTAWTLVHIALKPEERALYKNIPVIFNIERGFFFFEPDEERGEIKICDEHPGYTNMV  
QSADGTMMSIPFEKTQIPKEAETRVRALLKETMPQLADRPFSFARICWCADTANREFLI  
DRHPQYHSLVLGCGASGRGFKYLPSIGNLIVDAMEGKVPQKIHელიKNPDIAANRN  
WRDTLGRFGGPNRVMDFHDVKEWTNVQYRDISKL), in which the percentage identity is determined over an amino acid sequence of identical size to the amino acid sequence set forth in SEQ ID NO:3.

12. The isolated chimeric protein of claim 1, wherein the amadoriase binds to an antibody that specifically binds to an amino acid sequence set forth in SEQ ID NO:3.

13. The isolated chimeric protein of claim 1, wherein the amadoriase comprises the amino acid sequence set forth in SEQ ID NO:3.

14. The isolated chimeric protein of claim 1, wherein the first and second peptidyl fragments are linked via a cleavable linkage.

15. The isolated chimeric protein of claim 1, which further comprises, at its C-terminus, a third peptidyl fragment comprising a second bacterial leader sequence from about 5 to about 30 amino acid residues.

16. The isolated chimeric protein of claim 15, wherein the second bacterial leader sequence is a leader sequence of an *E.coli* protein.

17. The isolated chimeric protein of claim 15, wherein the second bacterial leader sequence has at least 40% identity to the amino acid sequence set forth in SEQ ID NO:4 (KGELEGLPIPNPLLRTG), in which the percentage identity is determined over an amino acid sequence of identical size to the amino acid sequence set forth in SEQ ID NO:4.

18. The isolated chimeric protein of claim 15, wherein the second bacterial leader sequence binds to an antibody that specifically binds to an amino acid sequence set forth in SEQ ID NO:4.

19. The isolated chimeric protein of claim 15, wherein the second bacterial leader sequence comprises the amino acid sequence set forth in SEQ ID NO:4.

20. The isolated chimeric protein of claim 15, wherein the third peptidyl fragment comprises about 20 amino acid residues.

21. The isolated chimeric protein of claim 1, which further comprises, at its C-terminus, a third peptidyl fragment comprising a peptide tag.

22. The isolated chimeric protein of claim 21, wherein the peptide tag is selected from the group consisting of FLAG, HA, HA1, c-Myc, 6-His, AU1, EE, T7, 4A6,  $\epsilon$ , B, gE and Ty1 tag.

23. The isolated chimeric protein of claim 15, which further comprises, at its C-terminus, a fourth peptidyl fragment comprising a peptide tag.

24. The isolated chimeric protein of claim 23, wherein the peptide tag is selected from the group consisting of FLAG, HA, HA1, c-Myc, 6-His, AU1, EE, T7, 4A6,  $\epsilon$ , B, gE and Ty1 tag.

25. The isolated chimeric protein of claim 1, which comprises the amino acid sequence set forth in SEQ ID NO:5

(MGGSGDDDDLALAVTKSSSLIVGAGTWGTSTALHLARRGYTNVTVLDPYPVPSAIS  
AGNDVNKVISSGQYSNNKDEIEVNEILAEAEFNGWKNDPLFKPYYHDTGLLMSACSQ  
EGLDRLGVRVRPGEDPNLVELTRPEQFRKLAPEGVLQGDFPGWKGYFARSGAGWAH  
ARNALVAAAREAQRMGVKFVTGTPQGRVVTLIFENNDVKGAVTGDGKIWRAERTFL  
CAGASAGQFLDFKNQLRPTAWTLVHIALKPEERALYKNIPVIFNIERGFFFEPEDEERGEI  
KICDEHPGYTNMVQSADGTMM SIPFEKTQIPKEAETRV RALLKETMPQLADRPFSFARI  
CWCADTANREFLIDRHPQYHSLVLGCGASGRGFKYLPSIGNLIVDAMEGKVPQKIHEL  
IKWNPDIAANRNWRDTLGRFGGPNRVMDFHDKVKEWTVNQYRDISKLKGELEGLPIP  
N PLLRTGHHHHHH).

26. An isolated nucleic acid comprising a nucleotide sequence encoding the chimeric protein of claim 1.

27. An isolated nucleic acid comprising a nucleotide sequence encoding the chimeric protein of claim 25.

28. The nucleic acid of claim 26, which comprises the nucleotide sequence set forth in SEQ ID NO:6

(ATGGGAGGTTTCGGGTGACGATGATGACCTGGCTCTCGCCGTCCTAAGTCATCAT  
CTCTCCTGATCGTTGGTGCCGGGACTTGGGGCACCTCAACGGCTCTGCACCTCGCG  
CGCCGCGGATATACCAACGTTACCGTGCTGGACCCCTATCCTGTCCCTAGCGCCAT  
CTCCGCGGAAACGACGTGAACAAAGTCATTAGCAGTGGCCAATATTCTGAATAAC  
AAAGACGAAATCGAAGTGAATGAGATCTTGCGGGAAGAGGCGTTTAACGGTTGGA  
AGAACGACCCGCTTTTCAAACCGTATTATCATGATACGGGCCTGCTGATGTCTGCT  
TGCTCGCAGGAGGGCCTGGATCGCCTGGGCGTCCGGGTACGTCCGGGCGAGGATC  
CTAATCTGGTGGAACCTTACCCGCCCCGAGCAATTTTCGTAAACTGGCCCCGGAAGG  
CGTGTTGCAAGGTGATTTTCCGGGTTGGAAAGGGTACTTTGCGCGTTCCGGCGCTG  
GCTGGGCACATGCAAGGAATGCCTTAGTGGCAGCAGCACGCGAAGCACAGCGCAT  
GGGTGTAAAATTTGTTACTGGCACCCCGCAGGGTCGTGTAGTCACGTTAATCTTTG  
AAAATAACGATGTAAAAGGTGCCGTTACGGGCGATGGCAAAATTTGGAGAGCGGA  
ACGTACATTCCTGTGTGCTGGGGCTAGCGCGGGTCAGTTCCTAGATTTCAAGAATC

AACTTCGACCAACCGCTTGGACCCTGGTACACATTGCGTTAAAACCGGAAGAACG  
TGC GTTGTACAAAAATATACCGGTTATCTTTAACATCGAACGGGGGTTTTTCTTTG  
AACCCGATGAGGAGCGCGGTGAGATTAATAATATGCGATGAACACCCGGGCTACAC  
AAATATGGTCCAGAGTGCAGACGGCACGATGATGAGCATTCCGTTTCGAAAAAACC  
CAGATTCCAAAAGAAGCCGAAACGCGCGTTCGGGCCCTGCTGAAAGAGACAATGC  
CCCAGCTGGCAGACCGTCCATTTCAGCTTCGCACGCATTTGCTGGTGTGCCGATACC  
GCGAATCGCGAATTCCTGATAGATCGACATCCGCAGTACCACAGTCTTGTGTTGGG  
CTGTGGTGCAGCGGAAGAGGGTTTAAATATCTGCCTTCTATTGGGAATCTCATTG  
TTGACGCGATGGAAGGTAAAGTGCCGCAAAAAATTCACGAATTAATCAAGTGGA  
CCCGGACATTGCGGCGAACCGTAACTGGCGTGATACTCTGGGGCGTTTTGGCGGTC  
CAAATCGTGTGATGGATTTTCATGATGTGAAGGAATGGACCAATGTTTCAGTATCGT  
GATATTTCCAAGCTGAAAGGAGAGTTGGAAGGTaaGCCAATCCCTAACCCGTTACT  
GCGCACAGGCCATCACCATCATCATCATTA).

29. An isolated nucleic acid comprising a nucleotide sequence complementary to the nucleotide sequence of claim 26.

30. A recombinant cell containing the nucleic acid of claim 26.

31. A method of producing a chimeric protein comprising growing a recombinant cell containing the nucleic acid of claim 26 such that the encoded chimeric protein is expressed by the cell, and recovering the expressed chimeric protein.

32. The product of the method of claim 31.

33. A method for assaying for a glycosylated protein in a sample, which method comprises:

- a) contacting a sample to be assayed with a protease to generate a glycosylated peptide or a glycosylated amino acid from a glycosylated protein, if contained in said sample;
- b) contacting said generated glycosylated peptide or glycosylated amino acid with a chimeric protein of claim 1 to oxidize said glycosylated peptide or glycosylated amino acid; and
- c) assessing oxidation of said glycosylated peptide or glycosylated amino acid by said chimeric protein to determine the presence and/or amount of said glycosylated protein in said sample.

34. The method of claim 33, wherein the sample is a blood sample.
35. The method of claim 34, wherein the blood sample is a plasma, serum, red blood cell or whole blood sample.
36. The method of claim 33, wherein the glycated protein to be assayed is glycoalbumin or glycohemoglobin.
37. The method of claim 33, wherein the protease is an endo-type protease or an exo-type protease.
38. The method of claim 37, wherein the endo-type protease is selected from the group consisting of trypsin,  $\alpha$ -chymotrypsin, subtilisin, proteinase K, papain, cathepsin B, pepsin, thermolysin, protease XVII, protease XXI, lysyl-endopeptidase, prolether and bromelain F.
39. The method of claim 37, wherein the exo-type protease is an aminopeptidase or a carboxypeptidase.
40. The method of claim 33, wherein the protease is selected from the group consisting of proteinase K, pronase E, ananase, thermolysin, subtilisin and cow pancreas proteases.
41. The method of claim 33, wherein the protease generates a glycated peptide from about 2 to about 30 amino acid residues.
42. The method of claim 33, wherein the protease generates glycated glycine, glycated valine or glycated lysine residue or a glycated peptide comprising glycated glycine, glycated valine or glycated lysine residue.
43. The method of claim 33, wherein the chimeric protein comprises the amino acid sequence set forth in SEQ ID NO:5.



44. The method of claim 33, wherein the chimeric protein is encoded by the nucleotide sequence set forth in SEQ ID NO:6.

45. The method of claim 33, wherein the oxidation of the glycated peptide or glycated amino acid is assessed by assessing consumption of the glycated peptide or glycated amino acid,  $H_2O$  or  $O_2$  in the oxidation reaction or the formation of the oxidized glucose (glucosone),  $H_2O_2$  or the amino acid in the oxidation reaction.

46. The method of claim 45, wherein the  $O_2$  consumption is assessed by an oxygen electrode.

47. The method of claim 45, wherein the  $H_2O_2$  formation is assessed by a peroxidase.

48. The method of claim 47, wherein the peroxidase is horseradish peroxidase.

49. The method of claim 47, wherein the  $H_2O_2$  formation is assessed by a peroxidase and Trinder reaction.

50. The method of claim 47, wherein the glycated peptide or glycated amino acid is contacted with the chimeric protein and the peroxidase sequentially or simultaneously.

51. The method of claim 45, wherein the glucosone formation is assessed by a glucose oxidase.

52. The method of claim 45, wherein the glucosone formation is assessed by a combination of glucose 6-phosphate dehydrogenase and hexokinase.

53. The method of claim 33, wherein the protease is inactivated before or current with the contact between the glycated peptide or glycated amino acid and the chimeric protein.

54. The method of claim 53, wherein the protease is inactivated by a heat treatment or an inhibitor of the protease.

55. The method of claim 33, wherein ascorbate interference is countered using a copper (II) compound, a cholic acid or a bathophenanthroline disulphonic acid or a mixture thereof.

56. The method of claim 33, wherein bilirubin interference is countered using a ferrocyanide salt.

57. The method of claim 33, which is used in the prognosis or diagnosis of a disease or disorder.

58. The method of claim 57, wherein the disease or disorder is diabetes.

59. A kit for assaying for a glycated protein in a sample, which kit comprises:

- a) a protease to generate glycated peptide or glycated amino acid from a glycated protein, if contained in a sample;
- b) a chimeric protein of claim 1 to oxidize said glycated peptide or glycated amino acid; and
- c) means for assessing oxidation of said glycated peptide or glycated amino acid by said chimeric protein to determine the presence and/or amount of said glycated protein in said sample.

60. The kit of claim 59, wherein the means for assessing oxidation of said glycated peptide or glycated amino acid by said chimeric protein comprises peroxidase.

61. The kit of claim 60, wherein the chimeric protein and the peroxidase are formulated in a single composition.

62. A method for assaying for a glycated protein in a sample, which method comprises:

- a) contacting a sample to be assayed with a proteinase K to generate a glycated peptide or a glycated amino acid from a glycated protein, if contained in said sample;
- b) contacting said generated glycated peptide or glycated amino acid with an amadoriase to oxidize said glycated peptide or glycated amino acid; and
- c) assessing oxidation of said glycated peptide or glycated amino acid by said amadoriase to determine the presence and/or amount of said glycated protein in said sample.

63. The method of claim 62, wherein the sample is a blood sample.

64. The method of claim 63, wherein the blood sample is a plasma, serum, red blood cell or whole blood sample.

65. The method of claim 62, wherein the glycated protein to be assayed is glycoalbumin or glycohemoglobin.

66. The method of claim 62, wherein the amadoriase comprises a chimeric protein, which chimeric protein comprises, from N-terminus to C-terminus:

- a) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and
- b) a second peptidyl fragment comprising an amadoriase.

67. The method of claim 66, wherein the chimeric protein comprises the amino acid sequence set forth in SEQ ID NO:5.

68. The method of claim 66, wherein the chimeric protein is encoded by the nucleotide sequence set forth in SEQ ID NO:6.

69. The method of claim 62, wherein the oxidation of the glycated peptide or glycated amino acid is assessed by assessing consumption of the glycated peptide or glycated amino acid,  $H_2O$  or  $O_2$  in the oxidation reaction or the formation of the oxidized glucose (glucosone),  $H_2O_2$  or the amino acid in the oxidation reaction.

70. The method of claim 69, wherein the  $O_2$  consumption is assessed by an oxygen electrode.

71. The method of claim 69, wherein the  $H_2O_2$  formation is assessed by a peroxidase.

72. The method of claim 71, wherein the peroxidase is horseradish peroxidase.

73. The method of claim 71, wherein the  $H_2O_2$  formation is assessed by a peroxidase and Trinder reaction.

74. The method of claim 71, wherein the glycated peptide or glycated amino acid is contacted with the amadoriase and the peroxidase sequentially or simultaneously.

75. The method of claim 69, wherein the glucosone formation is assessed by a glucose oxidase.

76. The method of claim 69, wherein the glucosone formation is assessed by a combination of glucose 6-phosphate dehydrogenase and hexokinase.

77. The method of claim 62, wherein the proteinase K is inactivated before or current with the contact between the glycated peptide or glycated amino acid and the amadoriase.

78. The method of claim 77, wherein the proteinase K is inactivated by a heat treatment or an inhibitor of the proteinase K.

79. The method of claim 62, wherein ascorbate interference is countered using a copper (II) compound, a cholic acid or a bathophenanthroline disulphonic acid or a mixture thereof.

80. The method of claim 62, wherein bilirubin interference is countered using a ferrocyanide salt.

81. The method of claim 62, which is used in the prognosis or diagnosis of a disease or disorder.

82. The method of claim 81, wherein the disease or disorder is diabetes.

83. A kit for assaying for a glycated protein in a sample, which kit comprises:

- a) a proteinase K to generate a glycated peptide or a glycated amino acid from a glycated protein, if contained in said sample;
- b) an amadoriase to oxidize said glycated peptide or glycated amino acid; and

c) means for assessing oxidation of said glycated peptide or glycated amino acid by said amadoriase to determine the presence and/or amount of said glycated protein in said sample.


84. The kit of claim 83, wherein the means for assessing oxidation of said glycated peptide or glycated amino acid by said amadoriase comprises peroxidase.

85. The kit of claim 84, wherein the amadoriase and the peroxidase are formulated in a single composition.

86. The kit of claim 83, wherein the amadoriase comprises a chimeric protein, which chimeric protein comprises, from N-terminus to C-terminus:

a) a first peptidyl fragment comprising a bacterial leader sequence from about 5 to about 30 amino acid residues; and

b) a second peptidyl fragment comprising an amadoriase.

**FIGURE 1**




FIGURE 2




FIGURE 3







FIGURE 4

**FIGURE 5**

## SEQUENCE LISTING

<110> General Atomics  
Yuan, Chong-Sheng  
Datta, Abhijit  
Wang, Yuping

<120> METHODS AND COMPOSITIONS FOR  
DETERMINATION OF GLYCATED PROTEINS

<130> 466992001340

<140> To Be Assigned

<141> Filed Herewith

<150> 10/622,893

<151> 2003-07-17

<160> 23

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> 40%-100% identity to leader sequence

<400> 1

Met Gly Gly Ser Gly Asp Asp Asp Asp Leu Ala Leu  
1 5 10

<210> 2

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> FAD cofactor-binding consensus sequence

<221> VARIANT

<222> 2, 4, 5

<223> Xaa = Any Amino Acid

<400> 2

Gly Xaa Gly Xaa Xaa Gly  
1 5

<210> 3

<211> 437

<212> PRT

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; 40%-100% identity to the amadoriase

&lt;400&gt; 3

Ala Val Thr Lys Ser Ser Ser Leu Leu Ile Val Gly Ala Gly Thr Trp  
 1 5 10 15  
 Gly Thr Ser Thr Ala Leu His Leu Ala Arg Arg Gly Tyr Thr Asn Val  
 20 25 30  
 Thr Val Leu Asp Pro Tyr Pro Val Pro Ser Ala Ile Ser Ala Gly Asn  
 35 40 45  
 Asp Val Asn Lys Val Ile Ser Ser Gly Gln Tyr Ser Asn Asn Lys Asp  
 50 55 60  
 Glu Ile Glu Val Asn Glu Ile Leu Ala Glu Glu Ala Phe Asn Gly Trp  
 65 70 75 80  
 Lys Asn Asp Pro Leu Phe Lys Pro Tyr Tyr His Asp Thr Gly Leu Leu  
 85 90 95  
 Met Ser Ala Cys Ser Gln Glu Gly Leu Asp Arg Leu Gly Val Arg Val  
 100 105 110  
 Arg Pro Gly Glu Asp Pro Asn Leu Val Glu Leu Thr Arg Pro Glu Gln  
 115 120 125  
 Phe Arg Lys Leu Ala Pro Glu Gly Val Leu Gln Gly Asp Phe Pro Gly  
 130 135 140  
 Trp Lys Gly Tyr Phe Ala Arg Ser Gly Ala Gly Trp Ala His Ala Arg  
 145 150 155 160  
 Asn Ala Leu Val Ala Ala Ala Arg Glu Ala Gln Arg Met Gly Val Lys  
 165 170 175  
 Phe Val Thr Gly Thr Pro Gln Gly Arg Val Val Thr Leu Ile Phe Glu  
 180 185 190  
 Asn Asn Asp Val Lys Gly Ala Val Thr Gly Asp Gly Lys Ile Trp Arg  
 195 200 205  
 Ala Glu Arg Thr Phe Leu Cys Ala Gly Ala Ser Ala Gly Gln Phe Leu  
 210 215 220  
 Asp Phe Lys Asn Gln Leu Arg Pro Thr Ala Trp Thr Leu Val His Ile  
 225 230 235 240  
 Ala Leu Lys Pro Glu Glu Arg Ala Leu Tyr Lys Asn Ile Pro Val Ile  
 245 250 255  
 Phe Asn Ile Glu Arg Gly Phe Phe Phe Glu Pro Asp Glu Glu Arg Gly  
 260 265 270  
 Glu Ile Lys Ile Cys Asp Glu His Pro Gly Tyr Thr Asn Met Val Gln  
 275 280 285  
 Ser Ala Asp Gly Thr Met Met Ser Ile Pro Phe Glu Lys Thr Gln Ile  
 290 295 300  
 Pro Lys Glu Ala Glu Thr Arg Val Arg Ala Leu Leu Lys Glu Thr Met  
 305 310 315 320  
 Pro Gln Leu Ala Asp Arg Pro Phe Ser Phe Ala Arg Ile Cys Trp Cys  
 325 330 335  
 Ala Asp Thr Ala Asn Arg Glu Phe Leu Ile Asp Arg His Pro Gln Tyr  
 340 345 350  
 His Ser Leu Val Leu Gly Cys Gly Ala Ser Gly Arg Gly Phe Lys Tyr  
 355 360 365  
 Leu Pro Ser Ile Gly Asn Leu Ile Val Asp Ala Met Glu Gly Lys Val  
 370 375 380  
 Pro Gln Lys Ile His Glu Leu Ile Lys Trp Asn Pro Asp Ile Ala Ala  
 385 390 395 400  
 Asn Arg Asn Trp Arg Asp Thr Leu Gly Arg Phe Gly Gly Pro Asn Arg  
 405 410 415  
 Val Met Asp Phe His Asp Val Lys Glu Trp Thr Asn Val Gln Tyr Arg  
 420 425 430  
 Asp Ile Ser Lys Leu  
 435

<210> 4  
 <211> 17  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> 40%-100% identity of the second bacterial leader sequence

<400> 4  
 Lys Gly Glu Leu Gly Leu Pro Ile Pro Asn Pro Leu Leu Arg Thr  
 1 5 10 15  
 Gly

<210> 5  
 <211> 472  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> chimeric protein

<400> 5  
 Met Gly Gly Ser Gly Asp Asp Asp Asp Leu Ala Leu Ala Val Thr Lys  
 1 5 10 15  
 Ser Ser Ser Leu Leu Ile Val Gly Ala Gly Thr Trp Gly Thr Ser Thr  
 20 25 30  
 Ala Leu His Leu Ala Arg Arg Gly Tyr Thr Asn Val Thr Val Leu Asp  
 35 40 45  
 Pro Tyr Pro Val Pro Ser Ala Ile Ser Ala Gly Asn Asp Val Asn Lys  
 50 55 60  
 Val Ile Ser Ser Gly Gln Tyr Ser Asn Asn Lys Asp Glu Ile Glu Val  
 65 70 75 80  
 Asn Glu Ile Leu Ala Glu Glu Ala Phe Asn Gly Trp Lys Asn Asp Pro  
 85 90 95  
 Leu Phe Lys Pro Tyr Tyr His Asp Thr Gly Leu Leu Met Ser Ala Cys  
 100 105 110  
 Ser Gln Glu Gly Leu Asp Arg Leu Gly Val Arg Val Arg Pro Gly Glu  
 115 120 125  
 Asp Pro Asn Leu Val Glu Leu Thr Arg Pro Glu Gln Phe Arg Lys Leu  
 130 135 140  
 Ala Pro Glu Gly Val Leu Gln Gly Asp Phe Pro Gly Trp Lys Gly Tyr  
 145 150 155 160  
 Phe Ala Arg Ser Gly Ala Gly Trp Ala His Ala Arg Asn Ala Leu Val  
 165 170 175  
 Ala Ala Ala Arg Glu Ala Gln Arg Met Gly Val Lys Phe Val Thr Gly  
 180 185 190  
 Thr Pro Gln Gly Arg Val Val Thr Leu Ile Phe Glu Asn Asn Asp Val  
 195 200 205  
 Lys Gly Ala Val Thr Gly Asp Gly Lys Ile Trp Arg Ala Glu Arg Thr  
 210 215 220  
 Phe Leu Cys Ala Gly Ala Ser Ala Gly Gln Phe Leu Asp Phe Lys Asn  
 225 230 235 240  
 Gln Leu Arg Pro Thr Ala Trp Thr Leu Val His Ile Ala Leu Lys Pro  
 245 250 255

Glu Glu Arg Ala Leu Tyr Lys Asn Ile Pro Val Ile Phe Asn Ile Glu  
 260 265 270  
 Arg Gly Phe Phe Phe Glu Pro Asp Glu Glu Arg Gly Glu Ile Lys Ile  
 275 280 285  
 Cys Asp Glu His Pro Gly Tyr Thr Asn Met Val Gln Ser Ala Asp Gly  
 290 295 300  
 Thr Met Met Ser Ile Pro Phe Glu Lys Thr Gln Ile Pro Lys Glu Ala  
 305 310 315 320  
 Glu Thr Arg Val Arg Ala Leu Leu Lys Glu Thr Met Pro Gln Leu Ala  
 325 330 335  
 Asp Arg Pro Phe Ser Phe Ala Arg Ile Cys Trp Cys Ala Asp Thr Ala  
 340 345 350  
 Asn Arg Glu Phe Leu Ile Asp Arg His Pro Gln Tyr His Ser Leu Val  
 355 360 365  
 Leu Gly Cys Gly Ala Ser Gly Arg Gly Phe Lys Tyr Leu Pro Ser Ile  
 370 375 380  
 Gly Asn Leu Ile Val Asp Ala Met Glu Gly Lys Val Pro Gln Lys Ile  
 385 390 395 400  
 His Glu Leu Ile Lys Trp Asn Pro Asp Ile Ala Ala Asn Arg Asn Trp  
 405 410 415  
 Arg Asp Thr Leu Gly Arg Phe Gly Gly Pro Asn Arg Val Met Asp Phe  
 420 425 430  
 His Asp Val Lys Glu Trp Thr Asn Val Gln Tyr Arg Asp Ile Ser Lys  
 435 440 445  
 Leu Lys Gly Glu Leu Glu Gly Leu Pro Ile Pro Asn Pro Leu Leu Arg  
 450 455 460  
 Thr Gly His His His His His His  
 465 470

&lt;210&gt; 6

&lt;211&gt; 1419

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; nucleotide sequence encoding a chimeric protein

&lt;400&gt; 6

atgggaggtt cgggtgacga tgatgacctg gctctcgccg tcactaagtc atcatctctc 60  
 ctgatcggtt gtgccgggac ttggggcacc tcaacggctc tgcacctcgc gcgccgcgga 120  
 tataccaacg ttaccgtgct ggacccctat cctgtcccta gcgccatctc cgccggaaac 180  
 gacgtgaaca aagtcattag cagtggccaa tattogaata acaaagacga aatcgaagtg 240  
 aatgagatct tggcgggaaga ggcgtttaac ggttggaaga acgacccgct tttcaaaccg 300  
 tattatcatg atacgggcct gctgatgtct gcttgctcgc aggagggcct ggatcgccctg 360  
 ggcgtccggg tacgtccggg cgaggatcct aatctggtgg aacttacccg cccggagcaa 420  
 tttcgtaaac tggccccgga aggcgtgttg caagggtgatt ttccgggttg gaaaggggtac 480  
 tttgcgcgtt ccggcgttg ctgggcacat gcaaggaatg ccttagtggc agcagcacgc 540  
 gaagcacagc gcatgggtgt aaaatttggt actggcacc cgcagggtcg tgtagtcacg 600  
 ttaatctttg aaaataacga tgtaaaagg gccgttacgg gcgatggcaa aatttgagga 660  
 gcggaacgta cattcctgtg tgctggggct agcgcgggtc agttcctaga tttcaagaat 720  
 caacttcgac caaccgcttg gaccctggta cacattgcgt taaaaccgga agaacgtgcg 780  
 ttgtacaaaa atataccggt tatctttaac atcgaacggg ggtttttctt tgaaccocag 840  
 gaggagcgcg gtgagattaa aatatgcat gaacacccgg gctacacaaa tatggtccag 900  
 agtgcagacg gcacgatgat gagcattccg ttcgaaaaaa cccagattcc aaaagaagcc 960  
 gaaacgcgcg ttcgggccct gctgaaagag acaatgcccc agctggcaga cctgccattc 1020  
 agcttcgcac gcatttgctg gtgtgccgat accgcgaatc gcgaattcct gatagatcga 1080  
 catccgcagt accacagtct tgtgttgggc tgtggtgcga gcggaagagg gtttaaatat 1140  
 ctgccttcta ttgggaatct cattgttgac gcgatggaag gtaaaagtgc gcaaaaaatt 1200  
 cacgaattaa tcaagtggaa cccggacatt gcggcgaacc gtaactggcg tgatactctg 1260

gggcgttttg gcggtccaaa tcgtgtgatg gattttcatg atgtgaagga atggaccaat 1320  
 gttcagtatc gtgatatttc caagctgaaa ggagagttgg aaggtaagcc aatccctaac 1380  
 ccgttactgc gcacaggcca tcaccatcat catcattaa 1419

<210> 7

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence homology between the N-terminal sequence of Amadoriases Ia

<221> VARIANT

<222> 12

<223> Xaa = C or T

<400> 7

Ala	Pro	Ser	Ile	Leu	Ser	Thr	Glu	Ser	Ser	Ile	Xaa	Val	Ile	Gly	Ala
1				5				10					15		
Gly	Thr	Trp	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly
			20				25						30		
Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly								
			35												

<210> 8

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence homology between the N-terminal sequence of Amadoriase Ib

<400> 8

Ala	Pro	Ser	Ile	Leu	Ser	Thr	Glu	Ser	Ser	Ile	Ile	Val	Ile	Gly	Ala
1				5				10					15		
Gly	Thr	Trp	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly
			20				25						30		
Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly								
			35												

<210> 9

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Sequence homology between the N-terminal sequence of Amadoriase Ic

<400> 9

Ser	Thr	Glu	Ser	Ser	Ile	Ile	Val	Ile	Gly	Ala	Gly	Thr	Trp	Gly	Cys
1				5				10					15		
Ser	Thr	Ala	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Leu
			20				25						30		
Leu	Leu	Leu	Leu	Leu	Leu	Leu	Leu								
			35												

<210> 10  
<211> 39  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Sequence homology between the N-terminal sequence of Amadoriase II

<400> 10  
Ala Val Thr Lys Ser Ser Ser Leu Leu Ile Val Gly Ala Gly Thr Trp  
1 5 10 15  
Gly Thr Ser Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr  
20 25 30  
Thr Thr Thr Thr Thr Thr Thr  
35

<210> 11  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> exemplary epitope tag

<400> 11  
Asp Tyr Lys Asp Asp Asp Lys  
1 5

<210> 12  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> exemplary epitope tag

<400> 12  
Tyr Pro Tyr Asp Val Pro Asp Tyr Ala  
1 5

<210> 13  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> exemplary epitope tag

<400> 13  
Cys Gln Asp Leu Pro Gly Asn Asp Asn Ser Thr  
1 5 10



<210> 14  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> exemplary epitope tag

<400> 14  
Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu  
1 5 10

<210> 15  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> exemplary epitope tag

<400> 15  
His His His His His His  
1 5

<210> 16  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> exemplary epitope tag

<400> 16  
Asp Thr Tyr Arg Tyr Ile  
1 5

<210> 17  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> exemplary epitope tag

<400> 17  
Glu Tyr Met Pro Met Glu  
1 5

<210> 18  
<211> 11  
<212> PRT  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; exemplary epitope tag

&lt;400&gt; 18

Ala Ser Met Thr Gly Gln Gln Met Gly Arg  
1 5 10

&lt;210&gt; 19

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; exemplary epitope tag

&lt;400&gt; 19

Ser Phe Pro Gln Phe Lys Pro Gln Glu Ile  
1 5 10

&lt;210&gt; 20

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; exemplary epitope tag

&lt;400&gt; 20

Lys Gly Phe Ser Tyr Phe Gly Glu Asp Leu Met Pro  
1 5 10

&lt;210&gt; 21

&lt;211&gt; 6

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; exemplary epitope tag

&lt;400&gt; 21

Gln Tyr Pro Ala Leu Thr  
1 5

&lt;210&gt; 22

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; exemplary epitope tag

&lt;400&gt; 22

Gln Arg Gln Tyr Gly Asp Val Phe Lys Gly Asp  
1 5 10

<210> 23

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> exemplary epitope tag

<400> 23

Glu Val His Thr Asn Gln Asp Pro Leu Asp  
1 5 10

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2004/022908

## Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
  - a. type of material
    - ☒ a sequence listing
    - ☐ table(s) related to the sequence listing
  - b. format of material
    - ☒ in written format
    - ☒ in computer readable form
  - c. time of filing/furnishing
    - ☒ contained in the international application as filed
    - ☐ filed together with the international application in computer readable form
    - ☒ furnished subsequently to this Authority for the purpose of search
2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N9/06 C12N15/62 C12Q1/37 C12Q1/26 G01N33/72

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, PAJ, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TAKAHASHI MOTOKO ET AL: "Molecular cloning and expression of amadoriase isoenzyme (fructosyl amine:oxygen oxidoreductase, EC 1.5.3) from Aspergillus fumigatus"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US,</p> <p>vol. 272, no. 19, 9 May 1997 (1997-05-09), pages 12505-12507, XP002189584</p> <p>ISSN: 0021-9258</p> <p>cited in the application</p> <p>page 12506, column 2, last paragraph;</p> <p>figure 1</p> <p style="text-align: center;">-----</p> <p style="text-align: center;">-/--</p>	1-32

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

5 January 2005

Date of mailing of the international search report

26/01/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Aslund, J

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	"pBAD TOPO TA Expression Kit" INVITROGEN CATALOGUE, 2002, page 75, XP002312415 Relevant to Seq Ids 1, 4 the whole document	3,17,18
X	EP 0 821 064 A (KYOTO DAIICHI KAGAKU KK) 28 January 1998 (1998-01-28) examples 1-7	33-86
X	YOSHIDA N ET AL: "Primary structures of fungal fructosyl amino acid oxidases and their application to the measurement of glycated proteins" EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 242, no. 3, 15 December 1996 (1996-12-15), pages 499-505, XP002089646 ISSN: 0014-2956 figure 2	33-86
X	EP 1 223 224 A (KIKKOMAN CORP ; KOYAMA YASUJI (JP); ARAI AYUMI (JP); KAJIYAMA NAOKI (J) 17 July 2002 (2002-07-17) page 4, line 44 - line 56; examples 4,5	62-65
A	TAKAHASHI MOTOKO ET AL: "Isolation, purification, and characterization of amadoriase isoenzymes (fructosyl amine-oxygen oxidoreductase EC 1.5.3) from Aspergillus sp" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 6, 7 February 1997 (1997-02-07), pages 3437-3443, XP002189585 ISSN: 0021-9258	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/022908

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0821064	A	28-01-1998	JP	10033177 A	10-02-1998
			DE	69720335 D1	08-05-2003
			DE	69720335 T2	04-03-2004
			EP	0821064 A2	28-01-1998
			US	5948659 A	07-09-1999
<hr/>					
EP 1223224	A	17-07-2002	JP	2001095598 A	10-04-2001
			EP	1223224 A1	17-07-2002
			WO	0125475 A1	12-04-2001
<hr/>					

